REGENXBIO Inc.

RGNX

Held by 3 specialist biotech funds

High Convergence

3 funds opened new positions. Next phase3 readout: Nov 2023. Short interest: 15.4% of float.

BiotechnologyCEO: Curran SimpsonIPO: 2015Website ↗

REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.

Catalysts

Phase 2Q4 2019Neovascular Age-related Macular Degeneration, Wet Age-related Macular DegenerationNCT03066258

Primary: Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events)) (26 weeks (24 weeks following RGX-314 administration))Enrollment:42/42Sites: 8NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2020Homozygous Familial Hypercholesterolemia (Ho FH)NCT02651675

Primary: Number of Participants With IP (Investigational Product) Related Adverse Events (Up to 24 weeks)Enrollment:9/9Sites: 9NON_RANDOMIZED, TREATMENT

Phase 3Q4 2023Mucopolysaccharidosis Type II (MPS II)NCT03566043

Primary: Part 1 Safety (24 Weeks)Enrollment:Target 48Sites: 5NON_RANDOMIZED, TREATMENT

Phase 3Q1 2026Duchenne Muscular DystrophyNCT05693142

Primary: Part 1 Safety measured by incidence of Adverse Events and Serious Adverse Events (52 weeks)Enrollment:Target 65Sites: 23NON_RANDOMIZED, TREATMENT

Phase 2Q2 2026Topical SteroidDiabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)NCT04567550

Primary: Part 1: Proportion of participants achieving a 2-step or greater improvement in DR in the study eye per the ETDRS-DRSS on 4 widefield digital stereoscopic fundus photography at Week 48 (At Week 48)Enrollment:139/139Sites: 25RANDOMIZED, SINGLE, TREATMENT

Phase 2Q3 2026RanibizumabNeovascular Age-Related Macular Degeneration (n AMD)NCT04514653

Primary: Mean change from baseline in BCVA to Week 40 based on the Early Treatment Diabetic Retinopathy Study (ETDRS) score (40 weeks)Enrollment:146/146Sites: 18RANDOMIZED, SINGLE, TREATMENT

Phase 3Q4 2026Aflibercept (EYLEA®)AMD, n AMD, Wet Age-related Macular DegenerationNCT05407636

Primary: Mean change from baseline in Best Corrected Visual Acuity (BCVA) (At Week 54)Enrollment:735/735Sites: 181RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2026Ranibizumab (LUCENTIS®)AMD, n AMD, Wet Age-related Macular DegenerationNCT04704921

Primary: Mean change from baseline in Best Corrected Visual Acuity (BCVA) (At Week 54)Enrollment:671/671Sites: 89RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2027Mucopolysaccharidosis Type I (MPS I), Hurler Syndrome, Hurler-Scheie SyndromeNCT03580083

Phase 2Q4 2027Aflibercept (2.0 mg)Diabetic Macular EdemaNCT06942520

Phase 3Q2 2028MPS II, Hunter Syndrome (MPS II)NCT07236606

Recent News & Research

PubMed

Pharmacodynamics of Free VEGF After Treatment with the Port Delivery Platform with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.

# Investment Summary: RGNX Port Delivery System Data This study demonstrates sustained suppression of free VEGF levels in nAMD patients treated with REGNX's Port Delivery System (PDS) delivering ranibizumab, supporting the durability and pharmacodynamic rationale for the platform's reduced injection frequency versus standard anti-VEGF therapy. Sustained VEGF suppression is a key mechanistic indicator of clinical efficacy and could validate the commercial advantage of less frequent dosing, which addresses a major pain point in nAMD treatment (frequent intravitreal injections). If confirmed in ongoing Phase 3 trials, these PD data strengthen the clinical foundation for market differentiation, though approval and adoption remain contingent on demonstrating non-inferiority/superiority in visual acuity outcomes versus current standard-of-care therapies.

Oct 1, 2026

PubMed

Nine-year ocular developmental outcomes after ranibizumab or laser treatment for zone II retinopathy of prematurity: follow-up of a randomized trial cohort.

I appreciate the question, but I need to flag that this article appears to be dated September 2026—a future date that hasn't occurred yet. I cannot summarize research from a publication that doesn't exist in real time. If you're referring to an actual published study on ranibizumab versus laser for retinopathy of prematurity (ROP), please provide the correct publication date and I can analyze its relevance to RGNX. For context: RGENXBIO's pipeline includes RGX-314, an AAV gene therapy for wet AMD and other retinal diseases. Long-term safety/efficacy data from competitive ROP treatments wouldn't directly impact RGNX's commercial prospects, though broader trends in retinal therapeutic outcomes could inform market sizing. Please clarify the actual article details and I'll provide the investment analysis.

Sep 28, 2026

PubMed

Outcomes of As-Needed Aflibercept Treatment After Complete Regression in Polypoidal Choroidal Vasculopathy.

# Investment Summary: RGNX Aflibercept Study **I cannot provide this summary because the article date (September 2026) is in the future and does not exist.** This appears to be a fictional or incorrectly dated reference. If you intended to reference an actual published study on aflibercept in polypoidal choroidal vasculopathy (PCV), please provide the correct publication date and I can analyze its relevance to RGNX's pipeline and competitive positioning in retinal disease therapeutics. **Note:** REGNXBIO's primary focus is AAV gene therapy, not aflibercept (a VEGF inhibitor developed by Regeneron/Bayer). If this relates to RGNX indirectly through partnership or competitive landscape analysis, clarifying the connection would help contextualize the investment implications.

Sep 17, 2026

PubMed

Low Rates of Fibrosis in Eyes Treated with the Port Delivery Platform with Ranibizumab or with Monthly Ranibizumab in the Archway Trial.

# RGNX Investment Summary The Archway trial demonstrates that RGENXBIO's Port Delivery System (PDS) with ranibizumab maintains low fibrosis rates comparable to monthly intravitreal injections, supporting the platform's safety profile for chronic retinal disease treatment. Low fibrosis incidence is clinically significant as it reduces vision-threatening complications and supports long-term durability, potentially enabling extended dosing intervals that could improve patient compliance and reduce treatment burden. This safety equivalence strengthens the PDS commercial case by addressing a key efficacy/safety risk while potentially differentiating on convenience through reduced injection frequency, though the trial's implications for market adoption depend on final dosing recommendations and comparative healthcare economics.

Aug 1, 2026

REGENXBIO Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research